Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study

Annals of the Rheumatic Diseases
Jun LiangLingyun Sun

Abstract

To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE). A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and anti-double-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells. From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2+/-9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2+/-3.3 to 3.2+/-2.8 and proteinuria decreased from 2505.0+/-1323.9 to 858.0+/-800.7 mg/24 h (all p<0.05, by paired t test, n=12). At 1-year follow-up in 13 patients, 2 had a relapse of proteinuria, while the other 11 continue to have decreased disease activity on minimal treatment. Anti-dsDNA levels decreased. Improvement in glomerular filtration rate was noted ...Continue Reading

Citations

Jul 25, 2012·Zeitschrift für Rheumatologie·J Voswinkel, A Chapel
Sep 8, 2012·Current Allergy and Asthma Reports·Sheryl MascarenhasStacy P Ardoin
Jan 9, 2013·Clinical Reviews in Allergy & Immunology·Jan VoswinkelAlain Chapel
Aug 10, 2013·World Journal of Pediatrics : WJP·Guo-Ping ZhengJianguo Xu
Oct 19, 2013·Biologicals : Journal of the International Association of Biological Standardization·Mirco BelingheriLuciana Ghio
Apr 12, 2011·Bone Marrow Transplantation·M E BernardoF Locatelli
Jun 8, 2012·Nature Medicine·Zheng Liu, Anne Davidson
May 6, 2011·Tissue Engineering. Part a·Ivan MartinAlan Tyndall
Mar 16, 2011·Journal of Biomedicine & Biotechnology·Daniel PerryLaurence Morel
Dec 12, 2012·Clinical & Developmental Immunology·Yur-Ren KuoChao-Long Chen
Dec 1, 2012·Stem Cells Translational Medicine·Guangwen RenYufang Shi
Nov 13, 2013·Nature Reviews. Rheumatology·Alan Tyndall
Jan 12, 2013·American Journal of Respiratory and Critical Care Medicine·Rebecca L ToonkelMarilyn K Glassberg
Nov 28, 2012·Autoimmunity Reviews·Paola CiprianiRoberto Giacomelli
Feb 13, 2014·QJM : Monthly Journal of the Association of Physicians·J J El-JawhariD McGonagle
Mar 7, 2014·Clinical Reviews in Allergy & Immunology·Qianjin Lu
Aug 26, 2014·Clinical Reviews in Allergy & Immunology·Bin LiuPatrick S C Leung
Sep 13, 2012·Clinical & Developmental Immunology·Alberto M Marmont du Haut Champ
Apr 20, 2011·Current Rheumatology Reports·Alana B Levine, Doruk Erkan
Sep 6, 2011·Stem Cell Reviews and Reports·Mohamed AbumareeBill Kalionis
May 24, 2013·The Veterinary Quarterly·Catharina De SchauwerEvelyne Meyer
Sep 6, 2013·Immunological Investigations·Margarita PesmatzoglouEftichia Stiakaki
Jan 1, 2013·Journal of Clinical Medicine·Yves-Marie Pers, Christian Jorgensen
Mar 25, 2014·Expert Opinion on Drug Discovery·Fernando E FigueroaAntonio La Cava
Apr 1, 2011·Expert Opinion on Biological Therapy·Jin WangJianming Tan
Aug 23, 2011·Expert Opinion on Biological Therapy·Alexander R Badiavas, Evangelos V Badiavas
Jul 3, 2015·Experimental and Therapeutic Medicine·Li-Xue GuanLong-Jun Dai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.